

1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION**COMMON NAME:** DEPO®-Testosterone Sterile Solution**USE:** Human product used for hormonal replacement therapy in the male.**MANUFACTURER/SUPPLIER:**THE UPJOHN COMPANY
7171 PORTAGE RD.
KALAMAZOO, MI 49001-0199**TELEPHONE NUMBERS:**(616) 323-5122 (24 Hours)
(616) 323-7555 (8:00 AM - 4:30 PM)**2. COMPOSITION/INFORMATION ON INGREDIENTS****INGREDIENT 1****COMMON NAME:** Cottonseed Oil.**% BY WEIGHT:** 60% to 80%**CAS NUMBER:** 8001-29-4**EXPOSURE LIMIT(S):** Not established.**INGREDIENT 2****COMMON NAME:** Testosterone Cypionate.**% BY WEIGHT:** 10% to 20%**CAS NUMBER:** 58-20-8**EXPOSURE LIMIT(S):**UPJOHN EXPOSURE LIMIT-TWA: 4 µg/m³**INGREDIENT 3****COMMON NAME:** Benzoic Acid, Benzyl Ester.**% BY WEIGHT:** 10% to 20%**CAS NUMBER:** 120-51-4**EXPOSURE LIMIT(S):** Not established.**EXPOSURE LIMIT(S) FOR THE MATERIAL:**

Not established.

3. HAZARDS IDENTIFICATION**PRIMARY ROUTE(S) OF EXPOSURE:** Skin contact, eye contact, ingestion or inhalation.**EFFECTS OF OVEREXPOSURE:** Testosterone cypionate may cause edema, nausea or adverse reproductive effects in both sexes and masculinization in the female and inhibition of testicular function in the male. Due to the cottonseed oil, the compound may be harmful when inhaled, ingested or in contact with skin, by causing eye or skin irritation. Information on the toxicity of cottonseed oil pertains to concentrations much higher than those normally found in therapeutic compounds.**MEDICAL CONDITIONS AGGRAVATED BY****EXPOSURE:** Known hypersensitivity to the drug; prostatic or mammary carcinomas; pregnancy; cardiac, hepatic or renal disease.**4. FIRST AID MEASURES****EYES:** Flush with water for 15 minutes. Hold eyelids open to assure complete contact with water.**SKIN:** Wash with soap and water. Remove contaminated clothing.**INHALATION:** Remove from exposure.**INGESTION:** Contact a physician or poison control center.**5. FIRE FIGHTING MEASURES****FLASH POINT:** Nonflammable.**LOWER EXPLOSION LIMIT (LEL):** Not applicable.**UPPER EXPLOSION LIMIT (UEL):** Not applicable.**EXTINGUISHING MEDIA:** Water, carbon dioxide, dry chemical, or polymer foam.**FIRE FIGHTING PROCEDURES:** Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes.**UNUSUAL FIRE OR EXPLOSION HAZARDS:** None.**HAZARDOUS COMBUSTION PRODUCTS:** Carbon monoxide. Carbon dioxide.**6. ACCIDENTAL RELEASE MEASURES****STEPS TO BE TAKEN IN CASE MATERIAL IS RELEASED OR SPILLED:** Provide ventilation and respiratory, skin and eye protection to prevent overexposure. Keep the product out of drains; prevent entry to surface water, groundwater and soil. Small spills should be absorbed with paper towels or other appropriate media. Large spills can be vacuumed or scooped and placed in a suitable container. Wash spill site with dilute bleach when pickup is complete.**7. HANDLING AND STORAGE****PRECAUTIONS FOR HANDLING AND STORING:**

Avoid contact with skin, eyes and clothing. Wash thoroughly after handling. Launder contaminated clothes before reuse. Store in a cool, dry place and protect from light. Keep out of the reach of children.

8. EXPOSURE CONTROLS/ PERSONAL PROTECTION**RESPIRATORY PROTECTION:** Not required.**VENTILATION:** Local exhaust.**PROTECTIVE GLOVES:** Rubber.**EYE PROTECTION:** Safety glasses with side shields.**OTHER PROTECTIVE EQUIPMENT:** Protective covering for exposed areas of skin.

9. PHYSICAL AND CHEMICAL PROPERTIES

APPEARANCE/PHYSICAL STATE: Liquid in 1- or 10-mL vials.

MOLECULAR WEIGHT: Mixture.

10. STABILITY AND REACTIVITY

STABILITY: Stable (testosterone cypionate).

PHYSICAL CONDITIONS TO AVOID: Sensitive to light, strong oxidizing agents and heat (cottonseed oil).

INCOMPATIBILITY WITH OTHER MATERIALS: None.

HAZARDOUS DECOMPOSITION PRODUCTS: None.

HAZARDOUS POLYMERIZATION: Does not occur.

11. TOXICOLOGICAL INFORMATION**ACUTE STUDIES:**

ORAL LD₅₀ (RAT): 1,700 mg/kg (benzyl benzoate).

ORAL LD₅₀ (MOUSE): 1,400 mg/kg (benzyl benzoate).

INTRAPERITONEAL LD₅₀ (MOUSE): >1 g/kg (testosterone cypionate); >500 mg/kg (benzyl benzoate).

OTHER STUDIES:

REPRODUCTION/FERTILITY: When human men were treated with testosterone propionate, a decrease in spermatogenesis occurred.

Approximately 33% exhibited rebound production after the cessation of treatment.

CARCINOGENICITY: Positive, IARC (testosterone).

12. DISPOSAL CONSIDERATIONS

WASTE DISPOSAL METHOD: Dispose of by incineration in accordance with applicable international, national, state, and/or local waste disposal regulations.

13. SHIPPING REGULATIONS

Not regulated for transportation by the United States Department of Transportation (DOT), International Maritime Organization (IMO), or International Air Transport Association (IATA). May be subject to state and/or local transportation requirements.

14. OTHER INFORMATION

REVIEWED BY: Health and Safety Regulatory Affairs.

DISCLAIMER: The MSDS information is believed to be correct but should only be used as a guide. The Upjohn Company disclaims any express or implied warranty as to the accuracy of the MSDS information and shall not be held liable for any direct, incidental or consequential damages resulting from reliance on the information.

15. LABELING

This drug is subject to FDA labeling requirements; therefore, it is exempt from the labeling requirements of the OSHA Hazard Communication Standard.

NDC 0009-0347-02

NDC 0009-0417-01

NDC 0009-0417-02